Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis

Trial ID or NCT#

NCT01093326

Status

not recruiting iconNOT RECRUITING

Purpose

This study is an extension to the study AC-058B201 and will investigate the long-term safety, tolerability and efficacy of ponesimod in patients with relapsing-remitting multiple sclerosis.

Official Title

Multicenter, Randomized, Double-blind, Parallel-group Extension to Study AC-058B201 to Investigate the Long-term Safety, Tolerability, and Efficacy of Three Doses of Ponesimod, an Oral S1P1 Receptor Agonist, in Patients With Relapsing-remitting Multiple Sclerosis

Eligibility Criteria

Ages Eligible for Study: 18 Years to 55 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. 1. Patients who completed study treatment at their regular Week 24 (End of treatment) visit within the core study AC-058B201. 2. Signed informed consent for participating in the extension study.
Exclusion Criteria:
  1. 1. Any clinically relevant medical or surgical condition, which, in the opinion of the investigator, would put the patient at risk by participating in the extension study.
View All Criteria
Show Less

Investigator(s)

Y. Joyce Liao, MD, PhD
Y. Joyce Liao, MD, PhD
Neuro-ophthalmology specialist
Stanford Medicine Professor of Ophthalmology and Professor of Neurology

Contact us to find out if this trial is right for you.

Contact

Angela Campbell
(650) 721-6188

View on ClinicalTrials.gov